Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Fresenius SE & Co. KGaA Call Transcript 2012

Jul 24, 2012

166_ip_2012-07-24_ab33272f-faf5-40ad-9124-757880358849.pdf

Call Transcript

Open in viewer

Opens in your device viewer

Fresenius Kabi – Creating a Global Leader in Transfusion Technology

Conference Call, July 23, 2012

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Acquisition Highlights Fenwal – a Leading Transfusion Technology Company

    • Extend Fresenius Kabi's transfusion technology product portfolio and regional presence
    • Create growth platform in the U.S. for Fresenius Kabi's transfusion technology products and medical devices
    • Utilize Fresenius Kabi's sales and marketing presence outside the U.S. to further commercialize Fenwal's product portfolio
  • -Establish a leading global position in transfusion technology

Fenwal – Key Facts

  • -Headquartered in Lake Zurich / Illinois
  • -Baxter spin-off, acquired by financial investors in 2007
    • Key financials 2011:
  • -Sales US\$ 614 m
  • -Adjusted EBITDA US\$ 90 m
  • -Approx. 4,900 employees
  • -State-of-the art research and development center in Lake Zurich
    • Five production plants – in Puerto Rico (2), in the Dominican Republic, France and Tunisia

Compelling Strategic Rationale

P
i
i
h
t
t
r
m
e
a
s
s
e
w
l
d
i
k
t
a
e
a
n
g
m
a
r
e
i
i
t
p
o
s
o
n		 S
k
i
i
i
S
k
i
d
U
E
t
t
t
t
r
o
n
g
m
a
r
e
p
o
s
o
n
n
c
o
r
e
m
a
r
e
p
r
e
s
e
n
c
e
n
u
r
o
p
e
a
n
;
-
d
d
l
A
i
P
i
f
i
L
i
A
i
k
t
t
t
s
e
e
c
e
s
a
a
c
c
a
n
a
n
m
e
r
c
a
m
a
r
e
s
-
P
f
i
f
i
t
t
t
t
e
r
e
c
s
r
a
e
g
c		 C
l
h
i
t
o
m
p
e
m
e
n
a
r
y
g
e
o
g
r
a
p
c
p
r
e
s
e
n
c
e
-
C
l
d
f
l
i
b
i
i
F
i
K
b
i
t
t
t
's
o
m
p
e
m
e
n
a
r
p
r
o
c
p
o
r
o
o
c
o
m
n
n
g
r
e
s
e
n
s
a
y
u
u
-
h
i
b
l
d
b
d
f
i
l
i
h
l
i
i
i
t
t
t
t
F
t
t
's
s
r
e
n
g
s
n
o
o
a
g
s
a
n
e
r
s
w
e
n
w
a
s
r
o
n
g
p
o
s
o
n
n
d
b
l
d
l
l
i
d
i
t
t
t
a
u
o
m
a
e
o
o
c
o
e
c
o
n
e
v
c
e
s
S
i
i
l
l
t
m
a
r
c
u
u
r
e
s
-
V
l
i
t
a
e
c
r
e
a
o
n
u
i
l
t
t
p
o
e
n
a		 d
i
b
i
f
i
h
l
d
i
h
I
F
K
t
t
t
t
t
's
n
r
o
u
c
e
r
e
s
e
n
u
s
a
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y
p
r
o
u
c
s
n
e
-
U
i
d
S
i
l
i
i
k
i
d
d
i
i
b
i
k
i
d
t
t
t
t
t
t
t
t
t
t
n
e
a
e
s,
u
z
e
s
m
a
r
e
n
g
a
n
s
r
u
o
n
n
e
w
o
r
o
u
s
e
h
U
S
f
F
l
d
t
t
's
e
o
r
e
n
w
a
p
r
o
u
c
s
S
i
i
f
i
d
i
i
d
i
l
t
t
t
&
g
n
c
a
n
r
e
e
n
e
a
n
c
o
s
s
n
e
r
g
e
s
n
p
r
o
c
o
n
s
a
e
s
v
u
y
u
-
,
k
i
d
d
i
i
i
t
t
t
m
a
r
e
n
g
a
n
a
m
n
s
r
a
o
n

Global Transfusion Technology Market – Attractive Growth and Consolidation Play

Market Size: €2.0 bn; Market Growth: 4 – 6% p.a.

Source: internal research; excluding autotransfusion and blood bank IT solutions

Fresenius Kabi: Well-Balanced Product Portfolio

Product Segment Medical Devices / Transfusion Technology

A
l
i
i
D
i
t
p
p
c
a
o
n
e
v
c
e
s		 T
f
i
T
h
l
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y
I
f
i
"
n
u
s
o
n
p
u
m
p
s
E
l
i
i
t
t
t
"
n
e
r
a
n
u
r
o
n
p
u
m
p
s
I
V
f
i
l
d
l
t
t
t
s
e
s
e
r
s
p
o
r
s
n
e
e
e
s
"
,
,
,
l
b
T
&
t
t
"
r
a
n
s
n
a
s
a
p
e
r
c
u
a
n
e
o
u
s
u
e
s		 B
l
d
i
i
d
t
"
o
o
p
r
o
c
e
s
s
n
g
e
q
u
p
m
e
n
a
n
b
l
d
b
o
o
a
g
s
A
h
i
d
i
"
p
e
r
e
s
s
e
v
c
e
s
A
f
i
d
i
t
t
"
u
o
r
a
n
s
u
s
o
n
e
v
c
e
s

Financials

    • Transaction initially financed from existing funds; enterprise value below proceeds of May 2012 capital increase
  • -Expected mid-term % revenue growth: mid-single digit
    • One-time integration costs: approx. €100 million; P&L effect mostly in 2013, Cash Flow effect 2013 through 2018
  • Expected cost synergies/margin upside of €60 million p.a. mid-term
  • -Transaction EPS neutral by 2014
  • Fresenius Kabi mid-term targets under review (€5.5 bn sales and €1.5 bn from Medical Devices/Transfusion Technology) – Update as part of Q2 presentation on August 1st

Share Information

Share key facts

Number of shares1 177,438,335 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de

WKN / ISIN 578560 / DE0005785604

ADR key facts

Ticker symbol FSNUY Exchange OTC-market Depositary bank Deutsche Bank

Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053Structure Sponsored Level I ADR

1as of June 30, 2012

Financial Calendar

0
1
0
8
2
0
1
2		 t
R
1
h
l
f
2
0
1
2
t
s
e
p
o
r
o
n
a
3
1
1
0
2
0
1
2		 d
t
R
1
3
2
0
1
2
t
s
r
t
e
p
o
r
o
n
q
u
a
r
e
r
–

Contact

Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Major Shareholding Notification 2026
May 15
Director's Dealing 2026
May 8
Regulatory Filings 2026
May 6
Quarterly Report 2026
May 6
Major Shareholding Notification 2026
Apr 16
Annual Report 2026
Apr 16
Regulatory Filings 2026
Apr 8
Director's Dealing 2026
Apr 1
Director's Dealing 2026
Mar 20
Director's Dealing 2026
Mar 16
View all filings →